BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

565 related articles for article (PubMed ID: 35303473)

  • 1. Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study.
    Rearte A; Castelli JM; Rearte R; Fuentes N; Pennini V; Pesce M; Barbeira PB; Iummato LE; Laurora M; Bartolomeu ML; Galligani G; Del Valle Juarez M; Giovacchini CM; Santoro A; Esperatti M; Tarragona S; Vizzotti C
    Lancet; 2022 Mar; 399(10331):1254-1264. PubMed ID: 35303473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of ChAdOx1 nCoV-19 and BBIBP-CorV vaccines against COVID-19-associated hospitalisation and death in the Seychelles infected adult population.
    Theresa Pool SN; Shroff EH; Chetty A; Lewis L; Nonhlanhla YZ; Abdool Karim SS
    PLoS One; 2024; 19(4):e0299747. PubMed ID: 38578809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity induced by the use of alternative vaccine platforms to deal with vaccine shortages in a low- to middle-income country: Results of two randomized clinical trials.
    Macchia A; Ferrante D; Bouzas MB; Angeleri P; Biscayart C; Geffner J; Mammana L; Zapiola I; López EL; Gentile A; Varese A; Mazzitelli I; García FDD; Sharff D; Lucconi V; Sujansky P; Mariani J; de Quirós FGB
    Lancet Reg Health Am; 2022 May; 9():100196. PubMed ID: 35128512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of heterologous COVID-19 vaccine regimens to deal with product shortage: A randomised clinical trial in an elderly population.
    Kundro MA; Losso MH; Macchia A; Pastor I; Alonso Serena M; Gestoso C; Moreno Macías L; Crupi F; Acosta MC; Ivalo S; Ghioldi M; Bouzas MB; Mammana L; Zapiola I; Mazzitelli I; Varese A; Geffner J; Biscayart C; Angeleri P; Lopez E; Gentile A; Ferrante D; de Quiros FGB
    Public Health Pract (Oxf); 2022 Dec; 4():100313. PubMed ID: 36090797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse events following immunization with ChAdOx1 nCoV-19 and BBIBP-CorV vaccine: A comparative study among healthcare professionals of Nepal.
    Rayamajhi S; Rafi MA; Tripathi N; Dongol AS; Pandey M; Rayamajhi S; Bhandari S; Shrestha P; Hasan MT; Hossain MG
    PLoS One; 2022; 17(8):e0272729. PubMed ID: 35947626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a COVID-19 Vaccine Campaign and SARS-CoV-2 Infection and Mortality Among Adults Aged 60 Years And Older in a Middle-Income Country.
    Macchia A; Ferrante D; Angeleri P; Biscayart C; Mariani J; Esteban S; Tablado MR; de Quirós FGB
    JAMA Netw Open; 2021 Oct; 4(10):e2130800. PubMed ID: 34714342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of mRNA-1273, BNT162b2, and BBIBP-CorV vaccines against infection and mortality in children in Argentina, during predominance of delta and omicron covid-19 variants: test negative, case-control study.
    Castelli JM; Rearte A; Olszevicki S; Voto C; Del Valle Juarez M; Pesce M; Iovane AN; Paz M; Chaparro ME; Buyayisqui MP; Markiewicz MB; Landoni M; Giovacchini CM; Vizzotti C
    BMJ; 2022 Nov; 379():e073070. PubMed ID: 36450402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the omicron outbreak in adults of 50 years and older in Argentina: a test-negative case-control study.
    González S; Olszevicki S; Gaiano A; Salazar M; Regairaz L; Varela Baino AN; Bartel E; Varela T; González Martínez VV; Pesci S; Marín L; Irassar JI; Ceriani L; Garcia E; Kreplak N; Estenssoro E; Marsico F
    Lancet Reg Health Am; 2023 Nov; 27():100607. PubMed ID: 37808936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of COVID-19 vaccines on hospitalization and death in Guilan, Iran: a test-negative case-control study.
    Heidarzadeh A; Amini Moridani M; Khoshmanesh S; Kazemi S; Hajiaghabozorgi M; Karami M
    Int J Infect Dis; 2023 Mar; 128():212-222. PubMed ID: 36572376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco.
    Zhang Y; Belayachi J; Yang Y; Fu Q; Rodewald L; Li H; Yan B; Wang Y; Shen Y; Yang Q; Mu W; Tang R; Su C; Xu T; Obtel M; Mhayi A; Razine R; Abouqal R; Zhang Y; Yang X
    BMC Public Health; 2022 Aug; 22(1):1584. PubMed ID: 35987605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study.
    Cerqueira-Silva T; Andrews JR; Boaventura VS; Ranzani OT; de Araújo Oliveira V; Paixão ES; Júnior JB; Machado TM; Hitchings MDT; Dorion M; Lind ML; Penna GO; Cummings DAT; Dean NE; Werneck GL; Pearce N; Barreto ML; Ko AI; Croda J; Barral-Netto M
    Lancet Infect Dis; 2022 Jun; 22(6):791-801. PubMed ID: 35366959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seroepidemiological assessment of SARS-CoV-2 vaccine responsiveness and associated factors in the vaccinated community of the Casablanca-Settat Region, Morocco.
    Ezzikouri S; Tajudeen R; Majidi H; Redwane S; Aqillouch S; Abdulaziz M; Aragaw M; Papa Fallah M; Sembuche S; Batcho S; Kabwe P; Gonese E; Laazaazia O; Elmessaoudi-Idrissi M; Meziane N; Ainahi A; Sarih M; Ogwell Ouma AE; Maaroufi A
    Sci Rep; 2024 Apr; 14(1):7817. PubMed ID: 38570577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of SARS-CoV-2 infection risks after primary vaccination with BNT162b2, BBIBP-CorV, or ChAdOx1-nCOV-19 and after homologous and heterologous booster vaccinations with these vaccines and evaluation of SARS-CoV-2 reinfection profiles.
    Djorwé S; Bousfiha A; Nzoyikorera N; Nyandwi J; Kawthar B; Malki A
    Biomedicine (Taipei); 2023; 13(3):31-48. PubMed ID: 37937059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of BNT162b2, BBIBP-CorV, Gam-COVID-Vac and ChAdOx1 nCoV-19 Vaccines Six Months after the Second Dose: A Longitudinal Prospective Study.
    Petrović V; Vuković V; Patić A; Marković M; Ristić M
    Vaccines (Basel); 2022 Dec; 11(1):. PubMed ID: 36679901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sinopharm's BBIBP-CorV Vaccine and ChAdOx1 nCoV-19 Vaccine Are Associated with a Comparable Immune Response against SARS-CoV-2.
    Abdelhafiz AS; Ali A; Kamel MM; Ahmed EH; Sayed DM; Bakry RM
    Vaccines (Basel); 2022 Sep; 10(9):. PubMed ID: 36146540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses.
    Thiruvengadam R; Awasthi A; Medigeshi G; Bhattacharya S; Mani S; Sivasubbu S; Shrivastava T; Samal S; Rathna Murugesan D; Koundinya Desiraju B; Kshetrapal P; Pandey R; Scaria V; Kumar Malik P; Taneja J; Binayke A; Vohra T; Zaheer A; Rathore D; Ahmad Khan N; Shaman H; Ahmed S; Kumar R; Deshpande S; Subramani C; Wadhwa N; Gupta N; Pandey AK; Bhattacharya J; Agrawal A; Vrati S; Bhatnagar S; Garg PK;
    Lancet Infect Dis; 2022 Apr; 22(4):473-482. PubMed ID: 34838183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the Antibody Responses Following Vaccination with AstraZeneca and Sinopharm.
    Anvari E; Ghamar Talepoor A; Eshkevar Vakili M; Karimi N; Ataollahi M; Najafi G; Kabelitz D; Ahmadi I; Kalantar K
    Iran J Immunol; 2022 Sep; 19(3):321-329. PubMed ID: 36190385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Argentinean cohort of patients with rheumatic and immune-mediated diseases vaccinated for SARS-CoV-2: the SAR-CoVAC Registry-protocol and preliminary data.
    Isnardi CA; Schneeberger EE; Kreimer JL; Luna PC; Echeverría C; Roberts K; de la Vega MC; Virasoro BM; Landi M; Quintana R; Exeni MED; Kogan N; Petkovic I; Pereira D; De Los Ángeles Correa M; Zelaya MD; Tissera Y; Elkin MSG; Pisoni CN; Alonso C; Cogo AK; Cosatti MA; García L; Retamozo C; de Los Ángeles Severina M; Nieto RE; Rosemffet M; Mussano E; Bertoli A; Savio VG; Cosentino V; Pons-Estel GJ
    Clin Rheumatol; 2022 Oct; 41(10):3199-3209. PubMed ID: 35760939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study.
    Hyams C; Marlow R; Maseko Z; King J; Ward L; Fox K; Heath R; Tuner A; Friedrich Z; Morrison L; Ruffino G; Antico R; Adegbite D; Szasz-Benczur Z; Garcia Gonzalez M; Oliver J; Danon L; Finn A
    Lancet Infect Dis; 2021 Nov; 21(11):1539-1548. PubMed ID: 34174190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of immune activation of the COVID vaccines: ChAdOx1, BNT162b2, mRNA-1273, BBIBP-CorV, and Gam-COVID-Vac from serological human samples in Hungary showed higher protection after mRNA-based immunization.
    Fodor E; Olmos Calvo I; Kuten-Pella O; Hamar E; Bukva M; Madár Á; Hornyák I; Hinsenkamp A; Hetényi R; Földes F; Brigitta Z; Jakab F; Kemenesi G; Lacza Z
    Eur Rev Med Pharmacol Sci; 2022 Jul; 26(14):5297-5306. PubMed ID: 35916830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.